Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable,locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised,open-label,multicentre, phase 3 trial |
| |
| Affiliation: | 1. Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK;2. Netherlands Cancer Institute, Amsterdam, Netherlands;3. Hospital Universitario 12 de Octubre, Madrid, Spain;4. The Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA;5. Institut Gustave Roussy, INSERM U981, University of Paris Saclay, Villejuif, France;6. Smilow Cancer Center, Yale University, New Haven, CT, USA;7. Kyoto University, Kyoto, Japan;8. Sungkyunkwan University Samsung Medical Center, Seoul, South Korea;9. University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea;10. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola, Italy;11. Universitätsklinikum Münster, Münster, Germany;12. Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece;13. BC Cancer, Vancouver, BC, Canada;14. Department of Clinical Medicine, Macquarie University, Sydney, NSW, Australia;15. Juravinski Cancer Centre, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada;p. Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC, Canada;q. Saint Elizabeth''s Hospital, Mokotów Medical Center, Warsaw, Poland;r. Department of Medical Oncology, Athens Medical Center, Marousi, Greece;s. North-Western State Medical University, Saint Petersburg, Russia;t. Medical Oncology, Vall d''Hebron Institute of Oncology, Hospital Universitari Vall d''Hebron, Vall d''Hebron Barcelona Hospital Campus, Barcelona, Spain;u. Hospital Sao Lucas da PUCRS/Grupo Oncoclinicas, Porto Alegre, Brazil;v. Hospital Universitario Virgen del Rocío, Seville, Spain;w. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;x. AstraZeneca, Cambridge, UK;y. AstraZeneca, Gaithersburg, MD, USA;z. Beth Israel Deaconess Medical Center and PSMAR-IMIM Research Lab, Harvard Medical School, Boston, MA, USA |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
